colistimethate sodium (TQD3524) / Sino Biopharm - LARVOL DELTA

TQD3524-II-02: Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumonia • Respiratory Diseases

TQD3524-II-02: Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Apr 2026 ➔ Jul 2026

Trial initiation date • Infectious Disease • Pneumonia • Respiratory Diseases

Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Infectious Disease • Pneumonia • Respiratory Diseases

TQD3524-I-02: To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Renal Disease

TQD3524-I-02: To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Infectious Disease • Renal Disease